Retatrutide does cause nausea in a significant proportion of people who have received it in clinical trials. As an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, retatrutide shares the gastrointestinal side effect profile characteristic of the broader incretin-based drug class. Nausea is among the most commonly reported adverse events in Phase 2 trial data, occurring most frequently during dose escalation and at higher doses. This article explains how common nausea is, why it occurs, how it can be managed, and when to seek medical advice — drawing on published clinical evidence and UK regulatory guidance.

Nausea as a Side Effect of Retatrutide

Nausea is one of the most frequently reported side effects of retatrutide in clinical trials, consistent with the GLP-1 receptor agonist class, and is generally dose-dependent and most pronounced during dose escalation.

Retatrutide is an investigational triple receptor agonist currently under clinical development for the treatment of obesity and type 2 diabetes. It works by simultaneously activating three incretin-related receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This multi-receptor mechanism distinguishes it from existing approved therapies such as semaglutide or tirzepatide, and it is this broad pharmacological activity that underpins both its therapeutic potential and its side effect profile.

Nausea is one of the most frequently reported side effects associated with retatrutide in clinical trials to date, as documented in the Phase 2 randomised controlled trial published in the New England Journal of Medicine in June 2023 (Jastreboff et al., NEJM 2023). This is consistent with the broader class of GLP-1 receptor agonists, where gastrointestinal symptoms — particularly nausea, vomiting, and diarrhoea — are well-recognised and expected effects. The nausea associated with retatrutide is generally described as dose-dependent, meaning it tends to be more pronounced at higher doses and during the dose-escalation phase of treatment.

It is important to note that retatrutide has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for clinical use in the UK. As such, it is not currently available as a prescribed medicine outside of clinical trial settings. Any information about its side effects is therefore drawn from published trial data rather than post-marketing surveillance, and the full safety profile is still being established. Patients should not attempt to obtain retatrutide from unregulated or online sources; products sold outside of authorised clinical trials are unlicensed, unverified, and potentially unsafe.

How Common Is Nausea During Treatment

Nausea was reported in approximately 40–60% of participants receiving mid-to-high doses in the Phase 2 trial, with most episodes classified as mild to moderate and occurring early in treatment or after dose increases.

Based on data from the Phase 2 randomised controlled trial published in the New England Journal of Medicine in June 2023, nausea was reported as one of the most common adverse events among participants receiving retatrutide. Across the dose groups studied (1 mg, 4 mg, 8 mg, and 12 mg weekly subcutaneous doses), nausea rates varied according to the dose administered and the speed of dose escalation.

In that trial, gastrointestinal side effects — including nausea, vomiting, diarrhoea, and constipation — were collectively the most frequently reported adverse events. Nausea was reported in approximately 40–60% of participants in the mid-to-high dose groups (8 mg and 12 mg), with lower rates observed in participants receiving the smallest doses or following slower titration schedules. Nausea was most commonly reported during the early weeks of treatment or following each dose increase, and the majority of episodes were classified as mild to moderate in severity. Severe nausea leading to discontinuation of treatment occurred in a minority of participants.

These figures are broadly comparable to those reported with other GLP-1-based therapies such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro). Whether the additional glucagon receptor activity of retatrutide contributes to a higher rate of gastrointestinal side effects compared with GLP-1 monotherapy has not yet been established in head-to-head studies, and any such comparison should be interpreted cautiously.

It is also worth noting that clinical trial populations are carefully selected and monitored — participants with significant pre-existing gastrointestinal disease are typically excluded — and real-world rates of nausea may differ once a medicine reaches broader clinical use.

Why Retatrutide May Cause Digestive Symptoms

Retatrutide causes nausea primarily by slowing gastric emptying via GLP-1 receptor activation and stimulating brain regions involved in nausea, with rapid dose escalation and dietary habits also contributing.

Understanding why retatrutide causes nausea requires a brief look at its mechanism of action. GLP-1 receptor agonists are well established to slow gastric emptying — the rate at which food moves from the stomach into the small intestine. This effect is central to their ability to reduce appetite and promote feelings of fullness, but it also means that food and stomach contents remain in the stomach for longer than usual, which can trigger nausea, bloating, and discomfort. This mechanism is well documented in the prescribing information (Summary of Product Characteristics) for licensed GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), available via the electronic Medicines Compendium (eMC).

Retatrutide's additional activity at the glucagon receptor may further influence gastrointestinal motility and secretion; however, the precise contribution of glucagon receptor activation to the overall gastrointestinal side effect burden in humans has not yet been established, and this remains an area of active investigation.

Other factors that may contribute to nausea during retatrutide treatment include:

• Central nervous system effects: GLP-1 receptors are present in brain regions involved in nausea and vomiting, including the area postrema, and activation of these pathways is thought to contribute to the emetogenic effects of this drug class

• Dose escalation: Rapid increases in dose are more likely to provoke symptoms than gradual titration

• Individual variability: Genetic, metabolic, and lifestyle factors can influence how sensitive a person is to these effects

• Dietary habits: Eating large, fatty, or rich meals may worsen nausea in those taking GLP-1-based therapies

These mechanisms are not unique to retatrutide and are shared to varying degrees across the entire class of incretin-based medicines.

Managing Nausea and When to Seek Medical Advice

Eating smaller meals, avoiding fatty or spicy foods, and gradual dose titration can reduce nausea; seek urgent medical advice if you experience severe vomiting, dehydration, or upper abdominal pain radiating to the back.

For those participating in clinical trials of retatrutide, or for healthcare professionals seeking to understand the management of GLP-1-related nausea more broadly, several practical strategies are supported by clinical experience with similar licensed medicines.

Dietary and lifestyle adjustments that may help reduce nausea include:

• Eating smaller, more frequent meals rather than large portions

• Avoiding high-fat, spicy, or heavily processed foods

• Eating slowly and chewing food thoroughly

• Remaining upright for at least 30 minutes after eating

• Staying well hydrated, particularly if vomiting has occurred

• Avoiding alcohol, which can worsen gastrointestinal symptoms

In clinical trial settings, dose titration schedules are carefully managed to minimise the risk of severe nausea. If symptoms are particularly troublesome, the supervising clinician may slow the rate of dose escalation or temporarily reduce the dose. Anti-nausea medicines (antiemetics) may occasionally be considered, though their routine use alongside investigational medicines should always be discussed with the supervising medical team.

When to seek medical advice — red-flag symptoms

Patients or trial participants should seek prompt medical advice if they experience any of the following:

• Persistent or severe vomiting that prevents adequate fluid intake

• Signs of dehydration, such as dizziness, dark urine, or confusion — note that dehydration can precipitate acute kidney injury and requires urgent assessment

• Severe or persistent upper abdominal pain, particularly pain that radiates to the back, which may be accompanied by nausea, vomiting, or fever — this may indicate acute pancreatitis or gallbladder disease, both of which are recognised risks with GLP-1-based therapies and require urgent medical review

• Jaundice (yellowing of the skin or whites of the eyes)

• Significant unintentional weight loss beyond what is expected

• Any new or unexpected symptoms that cause concern

For urgent advice, contact NHS 111. If you experience severe or rapidly worsening abdominal pain, signs of serious illness, or are unable to keep any fluids down, call 999 or go to your nearest A&E department.

Suspected side effects from medicines — including those taken as part of a clinical trial — can be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. Both patients and healthcare professionals are encouraged to report.

What the Current Clinical Evidence Shows

Phase 2 trial data published in the NEJM in 2023 show gastrointestinal events including nausea were the most common side effects, were transient and self-limiting in most participants, and were more frequent at higher doses.

The most significant published evidence on retatrutide to date comes from a Phase 2 randomised controlled trial, the results of which were published in the New England Journal of Medicine in June 2023 (Jastreboff et al.). This trial enrolled adults with obesity (body mass index ≥30 kg/m², with or without type 2 diabetes) and assessed the efficacy and safety of retatrutide across multiple weekly subcutaneous doses (1 mg, 4 mg, 8 mg, and 12 mg) over a 24-week period, with some participants followed for up to 48 weeks.

The trial demonstrated substantial weight loss across all active dose groups. In participants without type 2 diabetes, the highest doses (8 mg and 12 mg) were associated with mean reductions in body weight of approximately 17% at 24 weeks. Gastrointestinal adverse events, including nausea, were consistently the most common side effects reported across all dose groups.

Key findings relevant to nausea included:

• Nausea was most prevalent during the dose-escalation phase and tended to diminish over time as participants adapted to the medication

• Higher doses were associated with higher rates of nausea and vomiting

• The majority of gastrointestinal events were transient and self-limiting

• Discontinuation due to gastrointestinal side effects occurred in a small but notable proportion of participants, particularly in higher-dose groups

It should be noted that the weight-loss outcomes described above are from a Phase 2 trial and cannot be directly compared with those of licensed medicines without head-to-head data. Phase 3 trials are currently ongoing (see ClinicalTrials.gov for the retatrutide Phase 3 programme), and these larger studies will provide more robust data on the long-term safety and tolerability of retatrutide across more diverse populations. Until these trials are complete and regulatory submissions are made, the full picture of retatrutide's side effect profile — including the true burden of nausea in real-world use — remains to be established.

Talking to Your GP or Prescriber About Side Effects

If taking a related licensed medicine such as semaglutide or tirzepatide and experiencing nausea, discuss this with your GP or prescriber, who can advise on dose adjustment and symptom management in line with NICE guidance.

Because retatrutide is not yet licensed for use in the UK, most people will not currently be taking it outside of a clinical trial. If you are enrolled in a trial and experiencing nausea or other gastrointestinal symptoms, your first point of contact should always be the trial's medical team, who are best placed to advise on symptom management within the context of the study protocol. You should not attempt to obtain retatrutide from unregulated sources, including online suppliers; such products are unlicensed, unverified, and may pose serious risks to your health.

If you are taking a related licensed medicine — such as semaglutide (Ozempic or Wegovy) or tirzepatide (Mounjaro), which act on overlapping receptor pathways — and are experiencing nausea, it is entirely appropriate to discuss this with your GP or prescriber. Relevant UK guidance includes:

• NICE Technology Appraisal for semaglutide (Wegovy) in weight management — sets out the criteria for use and monitoring in adults with obesity

• NICE guideline NG28: Type 2 diabetes in adults: management — covers the use of incretin-based therapies in type 2 diabetes

• NICE Technology Appraisal for tirzepatide (Mounjaro) in type 2 diabetes — confirms the scope of UK recommendations for tirzepatide

Your prescriber can help assess whether your symptoms are expected, manageable, or warrant a change in treatment.

When speaking to your GP or prescriber, it may be helpful to:

• Keep a symptom diary noting when nausea occurs, how long it lasts, and any potential triggers

• Describe the severity of your symptoms honestly, including whether they are affecting your daily life or ability to eat and drink

• Mention any other medicines you are taking, as interactions may occasionally contribute to gastrointestinal symptoms

• Ask about dose adjustment if symptoms are persistent or distressing

If you develop severe or worsening abdominal pain, are unable to keep fluids down, or experience any of the red-flag symptoms described in the section above, contact NHS 111 for urgent advice or call 999/go to A&E if symptoms are severe. Suspected side effects from any medicine can be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Nausea is a recognised and manageable side effect of this class of medicines. Open communication with your healthcare team is the most effective way to ensure that treatment remains both safe and tolerable for you as an individual.

Frequently Asked Questions